LEXINGTON, Mass. - T2 Biosystems, Inc. (NASDAQ:TTOO), a company specializing in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has announced new territory exclusive distribution agreements to expand its commercial presence in the Netherlands, Belgium, Vietnam, and Switzerland. The agreements will enable T2 Biosystems to distribute its T2Dx Instrument and related sepsis test panels through local partners, aiming to improve the rapid diagnosis and treatment of sepsis in these regions.
The newly formed partnerships come as part of the company's strategy to increase its international market share. John Sperzel, Chairman and CEO of T2 Biosystems, stated that these agreements provide access to significant markets and the company anticipates growth potential for its rapid diagnostics. The move is also in line with efforts in Belgium and Switzerland to combat sepsis, with Belgium set to launch a national sepsis action plan in April 2024 and Swiss clinicians calling for a similar national plan.
The T2Dx Instrument offers the advantage of detecting sepsis-causing pathogens and antibiotic resistance genes within hours, a significant improvement over traditional methods that can take days. This technology is expected to enable clinicians to administer targeted therapies more quickly, potentially saving lives and reducing healthcare costs.
T2 Biosystems has established a track record of expansion, as evidenced by a large contract secured by Biomedica in Poland during 2023, and the company now seeks to replicate this success in Switzerland and other new markets. The significance of the expansion is underscored by statistics showing high rates of sepsis and antibiotic resistance in the target countries, with Vietnam reported to have the highest prevalence of resistance in a study of five Asia-Pacific countries.
The company's portfolio includes the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel. These products are based on T2 Magnetic Resonance (T2MR) technology, and T2 Biosystems continues to develop new diagnostics, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.